FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133851812> ?p ?o ?g. }

• W3133851812 endingPage "1304" @default.
• W3133851812 startingPage "1291" @default.
• W3133851812 abstract "Abstract CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to identify differences in efficacy and mechanism of action. In vitro, BCMAxCD3 bsAb efficiently induced polyclonal T-cell killing of primary human plasma cells and multiple myeloma (MM) cell lines expressing a range of BCMA cell surface densities. In vivo, BCMAxCD3 bsAb suppressed the growth of human MM tumors in murine xenogeneic models and showed potent combinatorial efficacy with programmed cell death protein 1 blockade. BCMAxCD3 bsAb administration to cynomolgus monkeys was well tolerated, resulting in the depletion of BCMA+ cells and mild inflammatory responses characterized by transient increases in C-reactive protein and serum cytokines. The antitumor efficacy of BCMAxCD3 bsAb was compared with BCMA-specific CAR T cells containing a BCMA-binding single-chain variable fragment derived from REGN5458. Both BCMAxCD3 bsAb and anti-BCMA CAR T cells showed similar targeted cytotoxicity of MM cell lines and primary MM cells in vitro. In head-to-head in vivo studies, BCMAxCD3 bsAb rapidly cleared established systemic MM tumors, whereas CAR T cells cleared tumors with slower kinetics. Thus, using the same BCMA-binding domain, these results suggest that BCMAxCD3 bsAb rapidly exerts its therapeutic effects by engaging T cells already in place at the tumor site, whereas anti-BCMA CAR T cells require time to traffic to the tumor site, activate, and numerically expand before exerting antitumor effects." @default.
• W3133851812 created "2021-03-15" @default.
• W3133851812 creator A5015053419 @default.
• W3133851812 creator A5015440255 @default.
• W3133851812 creator A5018299045 @default.
• W3133851812 creator A5022556675 @default.
• W3133851812 creator A5033731329 @default.
• W3133851812 creator A5045436636 @default.
• W3133851812 creator A5047499732 @default.
• W3133851812 creator A5049585139 @default.
• W3133851812 creator A5049721799 @default.
• W3133851812 creator A5050698920 @default.
• W3133851812 creator A5059361000 @default.
• W3133851812 creator A5064537451 @default.
• W3133851812 creator A5068034539 @default.
• W3133851812 creator A5077587801 @default.
• W3133851812 creator A5079288943 @default.
• W3133851812 creator A5090556615 @default.
• W3133851812 date "2021-03-02" @default.
• W3133851812 modified "2023-09-26" @default.
• W3133851812 title "A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells" @default.
• W3133851812 cites W1661103064 @default.
• W3133851812 cites W2031452426 @default.
• W3133851812 cites W2031724207 @default.
• W3133851812 cites W2057561528 @default.
• W3133851812 cites W2063733034 @default.
• W3133851812 cites W2105521580 @default.
• W3133851812 cites W2115531225 @default.
• W3133851812 cites W2118241155 @default.
• W3133851812 cites W2120529614 @default.
• W3133851812 cites W2153147430 @default.
• W3133851812 cites W2178103997 @default.
• W3133851812 cites W2194924429 @default.
• W3133851812 cites W2215319999 @default.
• W3133851812 cites W2293788518 @default.
• W3133851812 cites W2560267087 @default.
• W3133851812 cites W2594388103 @default.
• W3133851812 cites W2625253716 @default.
• W3133851812 cites W2787301955 @default.
• W3133851812 cites W2790173378 @default.
• W3133851812 cites W2790286570 @default.
• W3133851812 cites W2790574591 @default.
• W3133851812 cites W2795765610 @default.
• W3133851812 cites W2807637103 @default.
• W3133851812 cites W2864786814 @default.
• W3133851812 cites W2886837533 @default.
• W3133851812 cites W2887935186 @default.
• W3133851812 cites W2888019042 @default.
• W3133851812 cites W2893585523 @default.
• W3133851812 cites W2897100571 @default.
• W3133851812 cites W2899223835 @default.
• W3133851812 cites W2899334790 @default.
• W3133851812 cites W2914635378 @default.
• W3133851812 cites W2938308258 @default.
• W3133851812 cites W2943335541 @default.
• W3133851812 cites W2948141873 @default.
• W3133851812 cites W2951890667 @default.
• W3133851812 cites W2971490864 @default.
• W3133851812 cites W2973021197 @default.
• W3133851812 cites W2983001073 @default.
• W3133851812 cites W2983077705 @default.
• W3133851812 cites W2986629061 @default.
• W3133851812 cites W2997301227 @default.
• W3133851812 cites W2999417355 @default.
• W3133851812 cites W2999997703 @default.
• W3133851812 cites W3001702717 @default.
• W3133851812 cites W3017098331 @default.
• W3133851812 cites W4211037848 @default.
• W3133851812 cites W4235586867 @default.
• W3133851812 doi "https://doi.org/10.1182/bloodadvances.2020002736" @default.
• W3133851812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7948265" @default.
• W3133851812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33651100" @default.
• W3133851812 hasPublicationYear "2021" @default.
• W3133851812 type Work @default.
• W3133851812 sameAs 3133851812 @default.
• W3133851812 citedByCount "25" @default.
• W3133851812 countsByYear W31338518122021 @default.
• W3133851812 countsByYear W31338518122022 @default.
• W3133851812 countsByYear W31338518122023 @default.
• W3133851812 crossrefType "journal-article" @default.
• W3133851812 hasAuthorship W3133851812A5015053419 @default.
• W3133851812 hasAuthorship W3133851812A5015440255 @default.
• W3133851812 hasAuthorship W3133851812A5018299045 @default.
• W3133851812 hasAuthorship W3133851812A5022556675 @default.
• W3133851812 hasAuthorship W3133851812A5033731329 @default.
• W3133851812 hasAuthorship W3133851812A5045436636 @default.
• W3133851812 hasAuthorship W3133851812A5047499732 @default.
• W3133851812 hasAuthorship W3133851812A5049585139 @default.
• W3133851812 hasAuthorship W3133851812A5049721799 @default.
• W3133851812 hasAuthorship W3133851812A5050698920 @default.
• W3133851812 hasAuthorship W3133851812A5059361000 @default.
• W3133851812 hasAuthorship W3133851812A5064537451 @default.
• W3133851812 hasAuthorship W3133851812A5068034539 @default.
• W3133851812 hasAuthorship W3133851812A5077587801 @default.
• W3133851812 hasAuthorship W3133851812A5079288943 @default.
• W3133851812 hasAuthorship W3133851812A5090556615 @default.
• W3133851812 hasBestOaLocation W31338518121 @default.
• W3133851812 hasConcept C109316439 @default.

• next